Two CGD Families with a Hypomorphic Mutation in the Activation Domain of p67(phox) by Roos, Dirk et al.
Two CGD Families with a Hypomorphic Mutation in the 
Activation Domain of p67phox
Dirk Roos1,*, Jaap D van Buul1, Anton TJ Tool1, Juan D Matute2, Christophe M Marchal2, 
Bu’Hussain Hayee3, M Yavuz Köker4, Martin de Boer1, Karin van Leeuwen1, Anthony W 
Segal3, Edgar Pick5, and Mary C Dinauer2
1Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of 
Amsterdam, Amsterdam, The Netherlands 2Departments of Pediatrics (Hematology/Oncology), 
Microbiology/Immunology, and Medical and Molecular Genetics, Riley Hospital for Children, 
Indiana University School of Medicine, Indianapolis, IN, USA 3Department of Medicine, University 
College London, London, United Kingdom 4Department of Immunology and Immunology 
Laboratory, Faculty of Medicine, University of Erciyes, Kayseri, Turkey 5Julius Friedrich 
Cohnheim Laboratory of Phagocyte Research, Sackler School of Medicine, Tel Aviv University, 
Israel
Abstract
Study background—Chronic granulomatous Disease (CGD) is a rare immunodeficiency 
caused by a defect in the leukocyte NADPH oxidase. This enzyme generates superoxide, which is 
needed for the killing of bacteria and fungi by phagocytic leukocytes. Most CGD patients have 
mutations in CYBB, the X-linked gene that encodes gp91phox, the catalytic subunit of the 
leukocyte NADPH oxidase. We report here three autosomal recessive CGD patients from two 
families with a homozygous mutation in NCF2, the gene that encodes p67phox, the activator 
subunit of the NADPH oxidase.
Methods—Leukocyte NADPH oxidase activity, expression of oxidase components and gene 
sequences were measured with standard methods. The mutation found in the patients’ NCF2 gene 
was expressed as Ala202Val-p67phox in K562 cells to measure its effect on NADPH oxidase 
activity. Translocation of the mutated p67phox from the cytosol of the patients’ neutrophils to the 
plasma membrane was measured by confocal microscopy and by Western blotting after membrane 
purification.
Results—The exceptional feature of the A67 CGD patients reported here is that the p.Ala202Val 
mutation in the activation domain of p67phox was clearly hypomorphic: substantial expression of 
p67phox protein was noted and the NADPH oxidase activity in the neutrophils of the patients was 
20–70% of normal, dependent on the stimulus used to activate the cells. The extent of Ala202Val-
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p67phox translocation to the plasma membrane during cell activation was also stimulus dependent. 
Ala202Val-p67phox in K562 cells mediated only about 3% of normal oxidase activity compared to 
cells transfected with the wild-type p67phox.
Conclusion—The mutation found in NCF2 is the cause of the decreased NADPH oxidase 
activity and the (mild) clinical problems of the patients. We propose that the p.Ala202Val 
mutation has changed the conformation of the activation domain of p67phox, resulting in reduced 
activation of gp91phox.
Keywords
Chronic granulomatous disease; NADPH oxidase; p67phox; NCF2; p67phox activation domain; 
hypomorphic mutation; p67phox translocation
Introduction
Phagocytic leukocytes protect us against bacteria, yeasts and fungi by ingesting these micro-
organisms, followed by intracellular killing, or by attachment and extracellular killing. In 
this process, release of stored bactericidal proteins as well as generation of reactive oxygen 
species (ROS) by the phagocytes is essential [1]. Superoxide (O2−), as a precursor of other 
ROS, is produced by the leukocyte NADPH oxidase. This enzyme consists of two 
membrane-bound components, glycoprotein (gp)91phox (phox from phagocyte oxidase), also 
called Nox2, and p22phox, together forming flavocytochrome b558, and three cytosolic 
proteins called p40phox, p47phox and p67phox. The gp91phox protein is the catalytic subunit; it 
contains an NADPH binding site, one FAD and two heme prosthetic groups. The p22phox 
protein stabilizes gp91phox in membranes and also provides a docking site for the cytosolic 
p47phox subunit. The three cytosolic components form a tight complex that changes its 
conformation and translocates to the gp91phox/p22phox complex in the plasma membrane 
upon cell activation, e.g. after contact with micro-organisms [2]. Superoxide production also 
requires membrane translocation and activation of the small Rho GTPase Rac (preferentially 
Rac1 in macrophages and Rac2 in neutrophils), which subsequently binds to the 
tetratricopeptide regions (TPR) in p67phox (Supplementary Figure S1) and to the plasma 
membrane [2,3]. Following assembly and activation of the cytosolic subunits on 
flavocytochrome b558, the NADPH binding site of gp91phox becomes available for NADPH 
in the cytosol. NADPH donates two electrons to gp91phox, which are then transported within 
the protein to FAD, thereafter to the hemes, and finally to molecular oxygen at the other side 
of the membrane. Electron transfer requires Rac-activated p67phox binding to gp91phox as 
well as interactions between Rac and gp91phox [4]. In this way, superoxide is generated 
within the phagosome or on the cell surface, in close proximity to the ingested or attached 
micro-organisms.
Genetic failure of superoxide generation leads to a rare syndrome of recurrent, life-
threatening infections called Chronic Granulomatous Disease (CGD) [5]. The most common 
form of CGD (about 70% of all cases) is due to mutations in CYBB, the gene that encodes 
gp91phox [6]. Since CYBB is located on the X chromosome, this form of CGD is found 
almost exclusively in males. The autosomal forms of CGD are less common, with mutations 
in NCF1 (p47phox) in about 20% of cases and mutations in CYBA (p22phox) or NCF2 
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(p67phox) each in about 5% of cases [7]. A single patient with mutations in NCF4 (p40phox) 
has also been described [8]. Usually, these mutations lead to complete absence of the protein 
involved, but a few cases are known with diminished expression of gp91phox (resulting in 
diminished NADPH oxidase activity) or normal expression of completely inactive gp91phox 
[9]. We describe here three unusual CGD patients from two families with an identical 
mutation in NCF2, leading to diminished to near normal p67phox expression and substantial 
residual NADPH oxidase activity in their neutrophils. Expression of the mutated p67phox 
protein in a cellular test system proved this mutation to be the cause of the disease.
Materials and Methods
Cell purification
Blood samples were obtained from healthy controls, patients and their family members by 
their physician, following the procedures and appropriate consent protocols approved by the 
Human Subjects Committee of the hospitals involved. Total leukocytes were obtained by 
lysis of the erythrocytes in the pellet fraction with a non-fixing lysis solution of 155 mM 
NH4Cl, 10 mM NaHCO3 and 0.1 mM EDTA. Neutrophils were purified by centrifugation of 
the leukocyte fraction over a layer of Percoll with a specific gravity of 1.077 g/ml. The cells 
in the pellet (neutrophils) were suspended in Hepes medium [132 mM NaCl, 6 mM KCl, 1 
mM MgSO4, 1.2 mM KH2PO4, 20 mM Hepes, 5.5 mM glucose and 0.5% (wt/vol) human 
albumin (pH 7.4)], and the cells in the ring fraction (mononuclear leukocytes) were used for 
RNA purification.
NADPH oxidase tests
Oxygen consumption by neutrophils activated with serum-treated zymosan (STZ) or phorbol 
myristate acetate (PMA) was measured with an oxygen electrode [10]. The 
dihydrorhodamine-1,2,3 (DHR) test was performed with total leukocytes as described in 
Köker et al. [11]. This test measures the oxidation of DHR by hydrogen peroxide to the 
fluorescent compound rhodamine-1,2,3 on a per-cell basis in a flow cytometer by gating of 
the neutrophils on the basis of forward and side scatter. The nitro-blue tetrazolium (NBT) 
slide test was performed as described by Meerhof and Roos [12]. This test was performed 
with purified neutrophils and measures in a semi-quantitative way the reduction of NBT by 
superoxide to dark blue precipitates in each cell. The formation of superoxide by purified 
neutrophils was also measured by reduction of ferricytochrome c to ferrocytochrome c, 
followed in a spectrophotometer at 550 nm [13]. Finally, the secretion of hydrogen peroxide 
by purified neutrophils was evaluated in a 96-well plate with Amplex Red (Molecular 
Probes, Life Technologies, Carlsbad, CA, USA) and horse-radish peroxidase [14]. The 
resulting resorufin was measured over a period of 30 min in a plate reader (Genios Plus, 
Tecan, Männedorf, Switzerland) at 590 nm (excitation at 535 nm). The steepest part of the 
slope was used for calculating the maximal rate of H2O2 production.
Expression of NADPH oxidase components
The expression of gp91phox, p22phox, p47phox and p67phox was analyzed in a flow cytometer 
with permeabilized and fixed blood cells as described [11]. Western blot analysis was 
performed after SDS-10% PAGE of DFP-treated neutrophil lysates in 2-mercapto-ethanol, 
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transfer to nitrocellulose, blocking with 5% (w/v) milkpowder and incubation with mAb 
anti-p47phox (Santa Cruz Biotechnology, Santa Cruz, CA, USA; mouse-anti-human p47phox, 
clone 10, cat. no. SC-17845) and pAb anti-p67phox (Merck Millipore, Billerica, MA, USA; 
rabbit-anti-human p67phox, cat.no. 07-002). Conjugates were fluorescently labelled (LI-COR 
Biosciences, Lincoln, NE, USA), detected by scanning with the Odyssey Infrared Imagine 
System and quantified with Odyssey Application Software V3.0 (LI-COR).
Translocation of p67phox to the membrane in intact neutrophils
Neutrophils (5×106/ml, 1 ml) were stimulated with PMA (100 ng/ml) or STZ (1 mg/ml), 
washed once, and resuspended in 0.5 ml PBS with 0.1 mM diisopropyl fluorophosphate 
(DFP) for 10 min at 4°C. The cells were centrifuged and the pellet was resuspended in 100 
μl of digitonin for 10 min at 4°C; for PMA-stimulated neutrophils a concentration of 150 
μM digitonin in PBS was used, and for STZ stimulation a concentration of 300 μM digitonin 
in PBS. Thereafter, the cells were centrifuged (20 sec 20,000×g), the pellets were 
resuspended in Laemmli sample buffer and a Western blot was performed as described 
above. At these concentrations of digitonin, >90% of LDH was released from the cells and 
less than 5% of the protease content (data not shown), indicating proper separation of the 
cytosol and the rest of the cell.
For immunofluorescence, neutrophils were incubated with PMA (100 ng/ml) or left 
untreated for 10 minutes at 37°C in suspension. Next, the cells were allowed to adhere for 
10 minutes on fibronectin (10 ng/ml)-coated glass covers, followed by a 10-minute 
incubation with STZ (1 mg/ml) or PMA (100 ng/ml), or left untreated. Thereafter, the cells 
were fixed with 3.7% (w/v) formaldehyde for 10 minutes and permeabilized with 0.5% 
(w/v) Triton X-100 for 10 minutes. To visualize p67phox protein, the cells were incubated 
with the corresponding rabbit-anti-human antibody (Merck) for 30 minutes at room 
temperature, followed by a 30-minute incubation with a secondary goat-anti-rabbit-Ig 
ALEXA-568 antibody (Invitrogen). Coverslips were mounted with Vectashield (Vector 
Laboratories Inc., Peterborough, UK) on microscope slides and imaged with a confocal 
microscope through a 63× oil-objective (LSM510 META; Carl Zeiss MicroImaging, Inc.).
Expression and functional testing of recombinant p67phox in K562 cells
K562 cells, immature myeloid cell line cells that constitutively express p22phox, were first 
stably transfected with gp91phox cDNA in pEF-PGKpac [15] and then with p47phox cDNA 
in pEF-PGKhygro [16]. Cells were selected as individual clones in 2 μg/ml puromycin and 
250 μg/ml hygromycin for 3 weeks. A clone with high recombinant gp91phox and p47phox 
expression (K562-91-47) was used for further studies, and immunoblots were made as 
described [8]. K562-91-47 cells were transiently transfected with Amaxa by means of 
Nucleofector Kit V and protocol T-16kit V (Walkersville, MD, USA). Superoxide 
production by these cells was determined with isoluminol chemiluminescence in the 
presence of HRP as described [17].
Mutation analysis
Genomic DNA was isolated from total leukocytes by standard procedures and analyzed for 
mutations in NCF2 exons and exon-intron boundaries by PCR amplification of each exon 
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with its intronic boundaries, followed by bi-directional sequencing. The PCR conditions 
were as follows: 50 cycles of 5 s at 95°C, 30 s at 60°C and 15 s at 72°C, and for exon 16 50 
cycles of 5 s at 95°C, 30 s at 52°C and 15 s at 72°C. The PCR products were sequenced with 
the Big dye terminator sequencing kit v1.1 (Applied Biosystems, Foster City, CA, USA).
Total mRNA was purified from the mononuclear leukocyte fraction and converted into 
cDNA by means of Superscript III first-strand synthesis system for RT-PCR (Invitrogen, 
Carlsbad, CA, USA).
Case Presentations
Family A, a presumably non-consanguineous Turkish immigrant family with three 
daughters and one son, originally from the province of Tokat, Turkey, and now living in 
London, UK
Patient A1 (eldest female sibling), born 1970: This lady presented at age 17 with a 4-year 
history of recurrent cutaneous abscesses. These were controlled with antibiotics alone, and 
she managed minor flares of these on her own without the need to seek medical advice. She 
also has a chronic inflammatory, discoid lupus-like rash on her face. At age 30, she had an 
episode of peripheral ulcerative keratitis with adjacent conjunctival granulomata. The 
keratitis itself was non-granulomatous on biopsy. There was a recurrent episode of keratitis 
at age 35 (during the second trimester of pregnancy). Both episodes responded well to 
topical steroids and chloramphenicol drops. Since the diagnosis of CGD was made, the 
patient has been on trimethoprim-sulfamethoxazole and itraconazole prophylaxis. 
Neutrophil testing (ferricytochrome c reduction assay) revealed about 10% of normal 
NADPH oxidase activity with PMA.
Patient A2 (male sibling), born 1987: The male sibling was diagnosed with CGD at birth by 
NBT slide testing. He completed all childhood vaccinations without complications, but 
suffered from recurrent oral ulceration, leg ulcers, folliculitis and skin abscesses throughout 
childhood, controlled with repeated courses of topical and systemic antibiotics. Levels of all 
immunoglobulin sub-classes were normal. The patient has been taking trimethoprim-
sulfamethoxazole and itraconazole prophylaxis during the last twelve years. At age 19, he 
had a short episode of what was thought to be inflammatory bowel disease, with diarrhoea 
and rectal bleeding, although an MR-imaging of the abdomen at age 21 demonstrated no 
small or large bowel inflammation. He is currently in symptomatic remission with no history 
of other bacterial infections. Other members of this family did not present with medical 
problems.
Family B, Turkish family living in the province of Adana, Turkey, with no obvious relation 
to family A
The patient in this family is the only sibling, a girl born in 1990, whose parents are first 
cousins, with no history of early death in the family. She was referred to hospital at 8 years 
of age with diffuse pustular and eczematous lesions of the scalp skin, which were treated 
with systemic antibiotics, but without complete cure. CGD was diagnosed by impaired NBT 
test (all cells weakly positive). T cell function and lymphocyte subsets as well as CH50 were 
also normal. Her serum immunoglobulin levels were IgG 2380 mg/l, IgA 273 mg/l, IgM 73 
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mg/l, and IgE 71 mg/l, which is within normal limits. When she was 8 months of age, 
strabismus in the left eye was noticed after convulsions. During ophthalmological 
inspection, chorioretinitis and decreased vision in the left eye was diagnosed. She suffered 
repeatedly from chorioretinitis attacks in both eyes and has severe bilateral uveitis. At 
present, that has resulted in an almost 75% loss of vision in her left eye. She has been doing 
well for 10 years on prophylactic trimethoprim-sulfamethoxazole and itraconazole, at half 
dose during the last five years. Eczematous lesions of the scalp skin disappeared with Fe++ 
supplements. DHR analysis showed 5–10% of normal NADPH oxidase activity after 
stimulation of her neutrophils with PMA [11].
Results
All three patients had considerable NADPH oxidase activity, measured as oxygen 
consumption and as hydrogen peroxide release, in neutrophils activated by various stimuli 
(Figure 1A). This activity was about 50% of control values with unopsonized zymosan, 60–
70% with serum-treated zymosan (STZ), 15–25% with phorbol-myristate acetate (PMA) and 
20% with formyl-methionyl-leucyl-phenylalanine (fMLP) in platelet-activating factor 
(PAF)-primed neutrophils. The difference in residual NADPH oxidase activity in the 
patients’ cells activated with STZ as compared with PMA was highly significant, both in the 
oxygen consumption assay (p=0.009) and in the H2O2 release assay (p<0.0001). For 
comparison, neutrophils from two “classical” CGD patients (one with a one-nucleotide 
insertion in CYBA and another with a p.Arg102X nonsense mutation in NCF2) were also 
tested, in the same assay run. These neutrophils showed only 6% residual oxidase activity 
with unopsonized zymosan and 3% or less of control values with the other stimuli 
(Supplementary Table 1). The parents and sisters of patients A1 and A2 showed normal 
hydrogen peroxide release from their neutrophils (not shown). The mother of patient B 
showed normal hydrogen peroxide generation by her neutrophils in the DHR test (not 
shown). Western blots of neutrophil lysates from all three patients showed substantial 
expression of p47phox and p67phox (Figure 1B), as well as of gp91phox and p22phox (not 
shown).
We started DNA analysis by sequencing the exons and intron-exon boundaries of CYBB, as 
well as the first 600 nucleotides of its promoter region, because mutations are known in this 
gene to cause diminished expression of gp91phox and diminished NADPH oxidase activity 
[9]. However, no mutations were found in CYBB in these patients. We then investigated 
whether a common dinucleotide deletion in NCF1 was present, because deficiency of 
p47phox is known to leave some residual NADPH oxidase activity [18]. However, a gene 
scan [19] failed to detect this GT deletion in NCF1. We then sequenced the relevant parts of 
CYBA (from gDNA) and NCF1 (from cDNA) but found no mutations or indications for 
mRNA missplicing. Finally, in NCF2 we did find a homozygous c.605C>T mutation in all 
three patients, predicting p.Ala202Val in p67phox (Figure 2A). The parents and sisters of 
patients A1 and A2 were heterozygotes for the c. 605C>T mutation, as were the parents of 
patient B. In more than 100 healthy controls we did not observe this mutation. To investigate 
whether the mutant p67phox mRNA was as stable as the wild-type p67phox mRNA, we 
amplified the relevant part of p67phox cDNA in the mother of patient B and found both 
cDNA species to be present in similar amounts (Figure 2B). Moreover, the wild-type and the 
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mutated cDNA amplicon had a similar size, which rules out activation of a cryptic splice site 
by the mutation.
The question remained whether this mutation in p67phox was really the cause of the 
diminished NADPH oxidase activity in the neutrophils of the patients. To investigate this, 
we expressed the mutant p67phox Ala202Val and the wild-type p67phox in K562 cells stably 
transfected with p47phox and gp91phox and expressing endogenous Rac and p22phox. As 
shown in Figure 3A, both mutant and wild-type p67phox proteins were expressed in similar 
amounts in these cells. For comparison, we also expressed p67phoxVal204Ala in the K562 
cells, because this mutation, which – like Ala202Val – resides in the p67phox “activation 
domain” that is critical for activation of electron transport in gp91phox, has been shown in an 
in vitro system to lack all oxidase-activating potency [20,21]. Moreover, an Ala202Asn 
mutation in p67phox markedly reduces NADPH oxidase activity in a gp91phox-dependent 
whole cell system stimulated with PMA [21]. The p67phoxVal204Ala protein we used also 
contained a C-terminal myc tag, which does not have any effect on the superoxide 
production supported by p67phox wt-tagged protein [16]. Figure 3B shows that both the 
p67phox Ala202Val and the p67phox Val204Ala variant were far less effective than the wild-
type p67phox in inducing NADPH oxidase activity in PMA-activated K562 cells. In three 
separate experiments, the Ala202Val variant induced 2.7 ± 1% (S.D.) of wild-type p67phox-
induced oxidase activity, whereas the Val204Ala variant induced 1.0 ± 0.8% of wild-type 
p67phox-induced oxidase activity.
Finally, we studied the translocation of p67phox to the cell membrane after NADPH oxidase 
activation of neutrophils with two different assays, as described under Methods. The results 
are shown in Figure 4 and indicate that with PMA as the stimulus, the translocation of the 
p67phox protein from the cytosol to the membrane was clearly diminished, whereas with 
STZ, the translocation was close to normal. In control experiments with classical X-CGD 
neutrophils (without expression of gp91phox) the translocation of p67phox was completely 
absent with either PMA or STZ (Supplementary Figure S2).
Discussion
CGD patients with residual expression of NADPH oxidase components as well as residual 
NADPH oxidase activity are rare. Only four patients in three families have been described 
with low expression of p67phox and/or low NADPH oxidase activity [22–24]. The first of 
these had a deletion of one amino acid (Lys58) on one allele of NCF2 and an undefined 
large deletion on the other allele [22]. The Lys58-deleted protein was expressed to a certain 
extent (tested on Western blot with a polyclonal antibody against p67phox), but whether this 
was a normal expression (from one allele) or diminished expression could not be decided. 
The Lys58 deletion is in the fourth TPR domain and destroyed the interaction with Rac and 
the translocation of p67phox to the membrane in PMA- or STZ-activated neutrophils [22]. 
The NADPH oxidase activity in the neutrophils of this patient was completely absent with 
all stimuli tested. However, in the so-called cell-free system with recombinant proteins and 
neutrophil membranes, SDS and GTPγS did induce the translocation of these cytosolic 
proteins, although the NADPH oxidase activity was still absent.
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The second patient had a missense mutation in NCF2 that caused replacement of aspartic 
acid by valine at position 108 in p67phox [23]. This Asp108Val replacement is between the 
third and fourth TPR region in p67phox and left substantial residual NADPH oxidase activity 
(15–20% of normal) in the patient’s PMA-activated neutrophils (tested in the DHR assay). 
In a flow cytometric assay with permeabilized neutrophils, p67phox was undetectable with a 
monoclonal antibody. The authors speculate that the mutation may have changed the 
conformation of p67phox, rendering it undetectable with the monoclonal antibody used, but 
still able to interact to some extent with gp91phox for inducing some NADPH oxidase 
activity.
In the last family, two brothers were recognized as CGD patients when they were already in 
their fifties [24]. They had a splice site mutation in NCF2 that gave rise to an in-frame 
deletion of exons 11 and 12 (amino acids 309–342, PB1 domain). The neutrophils from 
these patients showed 10–15% of normal NADPH oxidase activity after stimulation with 
PMA in the DHR assay and in the lucigenin-enhanced chemiluminescence assay. This result 
was reproduced in K562 cells that contained all NADPH oxidase components except 
p67phox transduced with the Δexon11_12p67phox cDNA. The authors speculate that the 
p67phox protein with the exon11_12 deletion was to some extent expressed and functional in 
the patients’ phagocytes.
The hypomorphic mutation in the three patients described in this article is in the so-called 
Activation Domain of p67phox (Supplementary Figure S1). This stretch of twelve amino 
acids (199–210) is essential for the oxidase-inducing capacity of p67phox[20]. In a cell-free 
oxidase system, it was found that mutations in this domain do not affect binding of p67phox 
to p47phox or to Rac but do inhibit the oxidase activity [20]. Alanine-202 is highly conserved 
in p67phox from humans, mouse, chicken, frog, fish and lancelet, as well as in Noxa1 of 
humans, mouse and fish and in fungal NoxR [21]. Mutation of alanine-202 in p67phox into 
leucine inhibits the cell-free oxidase activity induced by arachidonic acid by about 50%, and 
a Val204Ala mutant totally blocks this activity. This last mutant associates with the 
membrane (presumably with gp91phox) as well as does the wild-type p67phox [20]. Direct 
interaction of p67phox with gp91phox was shown by Dang et al. [25,26] by overlay 
techniques and GST pull-down assays, but the Activation Domain of p67phox was not 
necessary for this reaction. Thus, the binding of p67phox to gp91phox is probably mediated by 
a site in p67phox different from the Activation Domain, but the induction of oxidase activity 
in gp91phox is strictly dependent on this domain. The site in gp91phox interacting with the 
Activation Domain of p67phox is not known.
The findings in our patients corroborate these notions and extend the findings to intact, 
primary phagocytes. We found partial inhibition of oxidase activity in the patients’ intact 
neutrophils with Ala202Val p67phox, as was found with the recombinant Ala202Leu variant 
of p67phox in the cell-free system [20]. Remarkably, much more oxidase activity was 
induced in the patients’ neutrophils with zymosan or STZ than with the soluble activators 
PMA or PAF/fMLP. This correlates with the normal translocation of p67phox to the 
membrane after neutrophil activation with STZ and clearly diminished translocation after 
activation with PMA. It suggests that the Ala202Val mutation in p67phox affects the 
translocation and – perhaps as a result – also the proper assembly or activation of the 
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NADPH oxidase complex following translocation of the cytosolic components to 
flavocytochrome b558 in the plasma membrane. This reduced translocation of Ala202Val-
p67phox might be due to reduced binding of p67phox to gp91phox, which would be in contrast 
to the conclusion drawn by Dang et al. from studies with purified neutrophil and 
recombinant proteins that the Activation Domain of p67phox does not interact with gp91phox 
[25,26]. Unfortunately, the 3D structure of the Activation Domain of p67phox is unknown 
[27–30]. However, it is known that different stimuli induce different activation pathways in 
neutrophils, especially with respect to the synthesis of various lipid products needed for 
assembly of an active oxidase complex [31–34]. The type or amount of lipid mediators 
generated in STZ-activated neutrophils may have been sufficient for almost normal oxidase 
activation by Ala202Val-p67phox, in contrast to the situation in PMA-activated neutrophils. 
Since lipid mediator generation in K562 cells may be different from neutrophils, this may 
also explain the low oxidase activation by Ala202Val-p67phox in transfected K562 cells as 
compared to the patients’ neutrophils. Alternatively, since the signal transduction pathway 
induced by PMA (protein kinase C activation leading to p47phox phosphorylation) is 
different from that induced by STZ (tyrosine phosphorylation of PI3 kinase leading to GEF 
and Rac activation), the translocation of p67phox to gp91phox and subsequent activation of 
gp91phox may be differently affected by mutations in p67phox. Thus, the p47phox-dependent 
pathway induced by PMA may be more sensitive to mutations leading to conformational 
changes in p67phox than the Rac-dependent pathway induced by STZ.
Our patients raise the question how much NADPH oxidase activity is required to be able to 
lead a normal life. The high residual oxidase activity in the patients’ neutrophils may have 
protected the patients to a certain extent from the full-blown CGD symptomatology. Indeed, 
their clinical problems were mild in comparison to those of oxidase-null CGD patients. On 
the other hand, it should be taken into account that we tested the neutrophil NADPH oxidase 
activity in in vitro assay systems, with strong stimuli. In vivo, more subtle stimuli may be 
encountered, with which the mutant p67phox may be unable to properly activate the NADPH 
oxidase. Thus, high residual NADPH oxidase activity in vitro is no guarantee for protection 
against pathogenic infections in vivo, but it may help in ameliorating the symptoms [35] and 
increase the chance of survival [36].
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Ala Alanine
Arg Arginine
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Asp Aspartic acid
CGD Chronic Granulomatous Disease
CH50 Complement Hemolysis 50%
CYBA Cytochrome b alpha
CYBB Cytochrome b beta
DHR Dihydrorhodamine-1,2,3
DFP Diisopropyl fluorophosphate
FAD Flavine Adenine Dinucleotide
fMLP formyl-methionyl-leucyl-phenylalanine
GEF Guanine nucleotide Exchange Factor
GTP Guanosine 5′-triphosphate
Lys Lysine
mAb Monoclonal antibody
MR Magnetic Resonance
NADPH Nicotinamide Adenine Dinucleotide Phosphate (reduced)
NBT Nitro-Blue Tetrazolium
NCF Neutrophil Cytosolic Factor
Nox NADPH oxidase
O2− Superoxide
pAb Polyclonal Antibody
PAF Platelet-Activating Factor
PAGE Polyacrylamide Gel Electrophoresis
PB1 Phox and Bem-1
PBS Phosphate-Buffered Salt
phox Phagocyte oxidase
PI3 Phospho-inositol-3
PMA Phorbol Myristate Acetate
ROS Reactive Oxygen Species
S.D. Standard Deviation
SDS Sodium dodecylsulphate
STZ Serum-Treated Zymosan
TPR Tetratricopeptide
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Val Valine
X-CGD X chromosome-linked CGD
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Figure 1. Characteristics of patients’ neutrophils
(A) NADPH-oxidase activity. Neutrophils were incubated with serum-treated zymosan 
(STZ, 1 mg/ml, 70 particles per neutrophil) or PMA (100 ng/ml), and the oxygen 
consumption was measured with an oxygen electrode (10). The maximal rate of oxygen 
consumption of patient cells is displayed in nmoles/min/106 cells. Alternatively, the release 
of hydrogen peroxide from the cells was measured with the Amplex Red assay (14) after 
stimulation with zymosan (1 mg/ml), STZ (1 mg/ml), PMA (100 ng/ml or PAF (1 μM) 
followed by fMLP (1 μM). The maximal rate of H2O2 release is displayed as 
nmoles/min/106 cells. Open bars, control neutrophils; closed bars, patient neutrophils 
(patients A1, A2, and B). Mean ± SEM of 3 (oxygen consumption) or 4 (H2O2 release) 
independent experiments (in the H2O2 release assay, one patient was tested twice). 
Significance of differences was calculated with the paired, two-tailed t-test. (B) Western blot 
of p47phox and p67phox. Neutrophils from a control donor (lane 1), patient B (lane 2), patient 
A1 (lane 3), patient A2 (lane 4) and a CGD patient with a p.Trp137Arg mutation in p67phox 
(lane 5) were lysed and subjected to SDS-PAGE as described under Methods. The proteins 
were blotted onto nitrocellulose, treated with antibodies to p47phox and to p67phox and 
visualized by fluorescence. The lower (green) band indicates the presence of p47phox, the 
upper (red) band the presence of p67phox.
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Figure 2. DNA and RNA sequencing of NCF2 (end exon 6)
Figure 2A shows the sequence obtained from genomic DNA of family A, with patients A1 
and A2 being homozygous for the c.605C>T mutation and all other family members 
heterozygous for this mutation. Figure 2B shows the sequence obtained with cDNA of 
patient B and her mother. The c.605C peak and the c.605T peak in the mother have a similar 
height, indicating that the mutated c.605T mRNA is as stable as the wild-type c.605C 
mRNA.
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Figure 3. Expression and function of p67phox in K562 cells
K562 cells containing all NADPH oxidase components except p67phox were transfected with 
cDNA encoding p67phoxAla202Val (p67A202), p67phoxVal204Ala with a myc-tag 
(p67V204myc) or p67phoxAla202 (p67wt). A representative Western blot in Figure 3A 
shows that all proteins were expressed in similar amounts in the cells. Figure 3B shows that 
upon activation with PMA, the mutated proteins did not support the oxidase activity in K562 
cells, in contrast to the wild-type protein.
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Figure 4. Translocation of p67phox to the cell membrane in intact neutrophils
(A) Quantification of p67phox translocation in stimulated human neutrophils. Human 
neutrophils (5×106/ml) were stimulated with PMA (100 ng/ml) for 10 min or with STZ (1 
mg/ml) for 20 min. Separation of cytosol and the rest of the cells, followed by Western blot 
analysis of p67phox was performed as described under Materials and Methods. The amount 
of p67phox was quantified by means of fluorescently labeled conjugates, and detected by 
scanning with the Odyssey Infrared Imagine System and Odyssey Application Software 
V3.0. Black bars, control neutrophils; Red bars, patient neutrophils (patient A1, A2, and B). 
Mean ± SEM of 3 independent experiments for PMA. With STZ only the cells of patient B 
were tested. Significance of differences was calculated with the paired, two-tailed t-test. (B) 
Visualization of p67phox translocation in stimulated human neutrophils. Neutrophils 
from a control donor and from patient B were incubated with PMA (100 ng/ml) or left 
untreated for 10 minutes at 37°C in suspension. The cells were then allowed to adhere on 
fibronectin-coated glass covers, followed by a 10-minute incubation with STZ (1 mg/ml) or 
left untreated. Thereafter, the cells were fixed with formaldehyde and permeabilized with 
Triton X-100. To visualize p67phox protein, the cells were incubated with rabbit-anti-human-
p67phox, followed by incubation with a secondary goat-anti-rabbit-Ig ALEXA-568-labeled. 
Coverslips were mounted with Vectashield on microscope slides and imaged with a confocal 
microscope through a 63× oil-objective. Note that with PMA, p67phox translocates to the 
plasma membrane of control neutrophils (arrows), but much less so to the plasma membrane 
of patient neutrophils. In contrast, translocation of p67phox to the phagosomal membrane 
surrounding internalized STZ (arrowheads) is similar in control and patient neutrophils.
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